Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)

Go back to Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
(NASDAQ: LEGN) Delayed: 29.34 +1.41 (5.05%)
Previous Close $27.93    52 Week High
Open $28.38    52 Week Low
Day High $29.46    P/E N/A 
Day Low $28.10    EPS
Volume 3,664,570